Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.37 +2.2%	$1.34	$0.86 ▼ $3.78	$299.66M	0.31	3.32 million shs	1.76 million shs
EXAI Exscientia	$4.84	$4.97	$3.80 ▼ $6.49	$632.93M	0.83	663,980 shs	N/A
INBX Inhibrx	$14.62 +0.3%	$12.55	$10.80 ▼ $17.79	$211.64M	N/A	105,229 shs	20,779 shs
RGNX REGENXBIO	$9.16 -1.2%	$8.53	$5.04 ▼ $15.36	$464.98M	1.09	927,112 shs	1.02 million shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-5.63%	+20.72%	-27.57%	-42.98%
EXAI Exscientia	0.00%	0.00%	0.00%	0.00%	-3.78%
INBX Inhibrx	0.00%	+4.67%	+18.17%	+4.52%	-7.20%
RGNX REGENXBIO	0.00%	-3.54%	+4.27%	+32.43%	-25.30%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.7881 of 5 stars	4.5	3.0	0.0	2.5	3.3	0.6
EXAI Exscientia	0.2177 of 5 stars	1.0	0.0	0.0	0.6	1.7	0.6
INBX Inhibrx	2.7188 of 5 stars	0.0	3.0	4.6	2.7	2.5	1.3
RGNX REGENXBIO	4.23 of 5 stars	3.4	2.0	4.6	2.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	516.38% Upside
EXAI Exscientia	2.00	Hold	$5.00	3.31% Upside
INBX Inhibrx	2.00	Hold	N/A	N/A
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	245.25% Upside

Current Analyst Ratings Breakdown

Latest RGNX, ALLO, EXAI, and INBX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/15/2025	INBX Inhibrx	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$12.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
4/17/2025	RGNX REGENXBIO	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $12.00
3/20/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00 ➝ $52.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$22K	13,620.98	N/A	N/A	$3.04 per share	0.45
EXAI Exscientia	$25.60M	24.72	N/A	N/A	$2.54 per share	1.91
INBX Inhibrx	$200K	1,058.20	N/A	N/A	N/A	∞
RGNX REGENXBIO	$156.72M	2.93	N/A	N/A	$7.09 per share	1.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$327.27M	-$1.23	N/A	N/A	N/A	N/A	-52.13%	-41.29%	8/6/2025 (Estimated)
EXAI Exscientia	-$181.56M	-$1.51	N/A	N/A	N/A	-882.09%	-49.10%	-33.13%	N/A
INBX Inhibrx	-$154.96M	$116.75	0.13	N/A	N/A	N/A	-113.74%	-80.56%	6/16/2025 (Estimated)
RGNX REGENXBIO	-$263.49M	-$3.11	N/A	N/A	N/A	-283.19%	-70.65%	-41.68%	8/7/2025 (Estimated)

Latest RGNX, ALLO, EXAI, and INBX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q4 2024	INBX Inhibrx	-$2.55	-$2.80	-$0.25	-$2.80	N/A	N/A
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
3/17/2025	Q4 2024	INBX Inhibrx	-$2.88	-$3.09	-$0.21	-$3.09	N/A	$0.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
EXAI Exscientia	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.35	9.35
EXAI Exscientia	0.06	4.54	4.54
INBX Inhibrx	N/A	4.70	4.70
RGNX REGENXBIO	N/A	3.05	3.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
EXAI Exscientia	41.58%
INBX Inhibrx	82.46%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
EXAI Exscientia	16.40%
INBX Inhibrx	17.09%
RGNX REGENXBIO	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	158.72 million	Optionable
EXAI Exscientia	280	130.77 million	109.32 million	Optionable
INBX Inhibrx	166	14.48 million	11.26 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.04 million	Optionable

RGNX, ALLO, EXAI, and INBX Headlines

Recent News About These Companies

Assenagon Asset Management S.A. Sells 283,399 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

June 16 at 3:49 AM | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Stock Price Up 6.1% - What's Next?

June 11, 2025 | marketbeat.com

REGENXBIO's (RGNX) "Buy" Rating Reiterated at Chardan Capital

June 11, 2025 | americanbankingnews.com

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts

June 9, 2025 | benzinga.com

REGENXBIO's (RGNX) Buy Rating Reaffirmed at Chardan Capital

June 9, 2025 | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives $31.63 Consensus PT from Analysts

June 8, 2025 | americanbankingnews.com

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

June 6, 2025 | seekingalpha.com

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update

June 6, 2025 | biopharmadive.com

RegeNXBio shares fall, despite positive new data on RGX-202

June 6, 2025 | thepharmaletter.com

Regenxbio’s Duchenne gene therapy data positive as shares falter

June 5, 2025 | bioworld.com

Regenxbio Fails To Best Sarepta’s Elevidys With New Data for DMD Gene Therapy

June 5, 2025 | biospace.com

REGENXBIO updates Phase 1/2 data for Duchenne candidate

June 5, 2025 | msn.com

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

June 5, 2025 | benzinga.com

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

June 5, 2025 | prnewswire.com

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

June 5, 2025 | marketbeat.com

REGENXBIO (NASDAQ:RGNX) Shares Up 13.5% - Still a Buy?

June 3, 2025 | marketbeat.com

Short Interest in REGENXBIO Inc. (NASDAQ:RGNX) Expands By 21.9%

June 3, 2025 | marketbeat.com

Bank of America Corp DE Reduces Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

June 3, 2025 | marketbeat.com

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

June 2, 2025 | prnewswire.com

Two Sigma Advisers LP Acquires 112,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

June 1, 2025 | marketbeat.com

Two Sigma Investments LP Acquires 263,495 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

June 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
By Leo Miller | June 14, 2025
View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY
By Thomas Hughes | June 11, 2025
View Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY

RGNX, ALLO, EXAI, and INBX Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.37 +0.03 (+2.24%)

Closing price 04:00 PM Eastern

Extended Trading

$1.36 -0.02 (-1.09%)

As of 07:51 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Exscientia NASDAQ:EXAI

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.

Inhibrx NASDAQ:INBX

$14.62 +0.05 (+0.34%)

Closing price 04:00 PM Eastern

Extended Trading

$14.62 0.00 (0.00%)

As of 04:02 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

REGENXBIO NASDAQ:RGNX

$9.16 -0.11 (-1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$9.12 -0.04 (-0.38%)

As of 05:57 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time